SPY749.60−0.63%QQQ674.25−0.83%BTC/USD66,661.30−2.30%DIA521.21−0.37%GLD355.70+0.07%TLT79.42+0.05%

Conmed Corp

CNMDNYSE

Trade with Public

$50.59

0.110.22%

At close: Nov 13, 4:00 PM EST

$50.59

N/A

After Hours: 4:00 PM EST

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Conmed (CNMD) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Conmed (CNMD) stock.

Analyst Consensus — 6 Analysts

4Buy

2Hold

# Analysts6

Latest Upgrades and Downgrades for Conmed Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	JP Morgan	Robbie Marcus	PT Raise	Neutral	$45→$50
—	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$46→$49
—	Piper Sandler	Matt O'Brien	PT Raise	Neutral	$39→$45
—	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$39→$46
—	BMO Capital	—	Initiate	Market Perform	$36
—	B of A Securities	Travis Steed	Downgrade	Neutral→Underperform	$40
—	B of A Securities	Travis Steed	PT Cut	Neutral	$52→$40
—	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$42→$39
—	JP Morgan	Robbie Marcus	PT Cut	Neutral	$43→$40
—	Piper Sandler	Matt O'Brien	Downgrade	Overweight→Neutral	$55→$39
—	Wells Fargo	Vik Chopra	PT Raise	Equal-Weight	$41→$42
—	Needham	Mike Matson	Maintained	Hold	—
—	B of A Securities	Travis Steed	PT Cut	Neutral	$65→$52
—	JP Morgan	Robbie Marcus	PT Cut	Neutral	$58→$52
—	Piper Sandler	Matt O'Brien	PT Cut	Overweight	$68→$55
—	Wells Fargo	Vik Chopra	PT Cut	Equal-Weight	$57→$47
—	Piper Sandler	Matt O'Brien	PT Cut	Overweight	$80→$68
—	Needham	Mike Matson	Downgrade	Buy→Hold	$61
—	JP Morgan	Robbie Marcus	PT Cut	Neutral	$70→$58
—	Wells Fargo	Vik Chopra	PT Cut	Equal-Weight	$70→$57

Conmed Corp

Conmed (CNMD) Stock Price Target 2026

Latest Upgrades and Downgrades for Conmed Stock

Conmed (CNMD) Stock Price Target 2026

Latest Upgrades and Downgrades for Conmed Stock

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on Conmed, Raises Price Target to $50

PRO
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $49

PRO
Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

PRO
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $46

PRO
BMO Capital Initiates Coverage On Conmed with Market Perform Rating, Announces Price Target of $36

PRO
B of A Securities Downgrades Conmed to Underperform, Maintains Price Target to $40

People Also Watch

People Also Watch

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on Conmed, Raises Price Target to $50

PRO
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $49

PRO
Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

PRO
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $46

PRO
BMO Capital Initiates Coverage On Conmed with Market Perform Rating, Announces Price Target of $36

PRO
B of A Securities Downgrades Conmed to Underperform, Maintains Price Target to $40

Conmed Corp

Conmed (CNMD) Stock Price Target 2026

Latest Upgrades and Downgrades for Conmed Stock

Conmed (CNMD) Stock Price Target 2026

Latest Upgrades and Downgrades for Conmed Stock

Analyst Ratings News

PROJP Morgan Maintains Neutral on Conmed, Raises Price Target to $50

PROWells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $49

PROPiper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

PROWells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $46

PROBMO Capital Initiates Coverage On Conmed with Market Perform Rating, Announces Price Target of $36

PROB of A Securities Downgrades Conmed to Underperform, Maintains Price Target to $40

People Also Watch

People Also Watch

Analyst Ratings News

PROJP Morgan Maintains Neutral on Conmed, Raises Price Target to $50

PROWells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $49

PROPiper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

PROWells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $46

PROBMO Capital Initiates Coverage On Conmed with Market Perform Rating, Announces Price Target of $36

PROB of A Securities Downgrades Conmed to Underperform, Maintains Price Target to $40

PRO
JP Morgan Maintains Neutral on Conmed, Raises Price Target to $50

PRO
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $49

PRO
Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

PRO
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $46

PRO
BMO Capital Initiates Coverage On Conmed with Market Perform Rating, Announces Price Target of $36

PRO
B of A Securities Downgrades Conmed to Underperform, Maintains Price Target to $40

PRO
JP Morgan Maintains Neutral on Conmed, Raises Price Target to $50

PRO
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $49

PRO
Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

PRO
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $46

PRO
BMO Capital Initiates Coverage On Conmed with Market Perform Rating, Announces Price Target of $36

PRO
B of A Securities Downgrades Conmed to Underperform, Maintains Price Target to $40